The Heart and Estrogen/progestin Replacement Study (HERS)

Maturitas

Volumn 31, Issue 1, 1998, Pages 9-14

  Speroff, Leon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; FRACTURE; GALLBLADDER DISEASE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; THROMBOEMBOLISM;

CLINICAL TRIALS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MEDROXYPROGESTERONE; PROGESTERONE CONGENERS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WOMEN'S HEALTH;

EID: 0032458920     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00104-2     Document Type: Article

References (38)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-18.
2. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1997;143:971-8.
3. Bush TL, Barrett-Connor E, Cowan DK, et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics program follow-up study. Circulation 1987;75:1102-9.
4. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
5. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Health Study. New Engl J Med 1991;325:756-62.
6. Derby CA, Hume AL, McPhillips JB, Barbour MM, Carleton RA. Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared to non-users. Am J Obstet Gynecol 1995;173:544-50.
7. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy: prevalence, compliance and the 'healthy women' notion. Climacteric 1998;1:42-9.
8. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.
9. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997;145:269-77.
10. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50.
11. O'Keefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997;29:1-5.
12. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111-8.
13. Jonas HA, Kronmal RA, Psaty BM, et al. Current estogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. Ann Epidemiol 1996;6:314-23.
14. Espeland MA, Applegate W, Furgerg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995;142:1011-9.
15. Liang Y-L, Teede H, Shiel L, et al. Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women. Clin Exp Pharmacol Physiol 1997;24:457-9.
16. Akkad A, Hartshorne T, Bell PRF, Al-Azzawi F. Carotid plaque regression on oestrogen replacement: a pilot study. Eur J Vasc Endovasc Surg 1996;11:347-8.
17. Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinicians formulation. Am J Obstet Gynecol 1998;179:S25-36.
18. Meilahn E, Kuller L, Matthews K, Kiss J. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445-55.
19. Scarabin PY, Flu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama M. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1994;70:584-7.
20. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
21. Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 1997;68:449-53.
22. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993;81:261-4.
23. De Sonza MJ, Nulsen JC, Sequenzia LC, Bona RD, Walker FJ, Luciano AA. The effect of medroxyprogesterone acetate on conjugated equine estrogen induced changes in coagulation parameters in postmenopausal women. J Womens Health 1996;5:121-8.
24. Boschetti C, Corteliaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs. oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:1-8.
25. Saleh AA, Dorey LG, Dombrowski MP, et al. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993;169:1554-7.
26. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas 1992;68:392-5.
27. Kessler CM, Szymanski LM, Shamsipour Z, Muesing RA, Miller VT, Larosa JC. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;89:325-31.
28. Bonduki CE, Lourenço DM, Baracat E, et al. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998;77:330-3.
29. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
30. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-61.
31. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-21.
32. Honore EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997;67:148-54.
33. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesteorne acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18:1164-71.
34. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
35. Schairer C, Adami H-O, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59-65.
36. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997;157:1330-6.
37. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and risk of cardiovascular disease. New Engl J Med 1996;335:453-61.
38. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. New Engl J Med 1997;336:1769-75.